Replies to post #45413 on OncoSec Medical Inc (ONCSQ)

[dangerM]

Hey hschlauch, thanks for sharing these important thoughts!

Just fyi, there might be an interesting SITC 2018 presentation on the basic science which confirms your emphasis on NK cells (looks as if they were the unknown link from anti-CTLA4 therapy to Treg depletion). No abstracts yet, so there is only the title:

SITC 2018

O40 Anti-CTLA4 activation of intratumoral NK cells may contribute to intratumoral Treg depletion

I also came across some poster from CRI-CIMT-EATI-AACR 2018 on twitter. Probably it only counts as anecdotic evidence (especially as it's impossible to decipher the data content, I was only able to transcribe the conclusions). It was the first time I consciously noticed NKT-cells (as different from NK-cells :)

Metastatic melanoma patients responding to PD1 therapy have higher proportion of peripheral blood NKT cells

#cicon18 NKT cells as a biomarker of PD1 therapy in melanoma by Henna Hakanen pic.twitter.com/TmZPNbdety

— HRUH hematology (@hruh_research) September 30, 2018

(only a look into EDTA and serum before, as well as 1 month and 3 months after anti-PD1, n = 19)

Conclusions
- Anti-PD1 therapy increases the levels of inflammation related chemokines in blood and expression of markers [not legible word: linked?] to enhanced cytotoxicity of NK cells
- High frequency of blood NKT cells associates with positive [not legible word] response, and in addition to T cells, NK and NKT cells may play a key role in the antitumor response induced by PD 1 inhibition
- Hence further research on the effect of anti-PD 1 therapy on NK and NKT cells is needed to better understand their role in positive therapy response.

Have a great day everyone (in spite of the market)

dM